Clobetasol
- Atc Codes:D07AD01
- CAS Codes:25122-46-7#25122-41-2
- PHARMGKB ID:25122-46-7#25122-41-2
Table of contents
- Brand Names
- Drug Combinations
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Toxicological Effects
- Genes that may be involved
- Drug Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Clarelux, Clobex, Dermovate; Belgium: Clarelux, Clobex, Dermovate; Bulgaria: Clobederm, Clovate, Dermovate; Cyprus: Clarelux, Decloban, Dermovate, Medodermone; Czech Republic: Clobex, Dermovate, Hoziac; Denmark: Clobex, Dermovat; Estonia: Dermovate; Finland: Clarelux, Clobex, Dermovat; France: Clobex, Dermoval; Germany: Butavate, Clarelux, Clobegalen, Clobetasol, Clobex, Dermoxin, Dermoxinale, Karison; Greece: Butavate, Clarelux, Clobex, Rubocord; Ireland: Clarelux, Dermovate, Etrivex; Italy: Clobesol, Olux; Latvia: Dermovate; Lithuania: Dermovate; Malta: Dermovate; Netherlands: Clarelux, Clobetasol, Clobex, Dermovate; Poland: Clarelux, Clobederm, Clobex, Dermklobal, Dermovate, Novate; Portugal: Clarelux, Dermovate, Etrivex; Romania: Clarelux, Clobetasol, Dermione, Dermovate; Slovakia: Clarelux, Clobex; Spain: Clarelux, Clobex, Clovate, Decloban; Sweden: Clobex, Dermovat; UK: Clarelux, Dermovate, Etrivex.
North America
Canada: Clobetasol, Clobex, Dermovate; USA: Clobetasol, Clobex, Cormax, Embeline, Olux, Temovate.
Latin America
Argentina: Clobesol, Clob-X, Dermaclob, Dermadex, Perfracort, Ribatra, Salac; Brazil: Clobesol, Clobetasol, Clob-X, Cortalen C, Dermacare, Propiosol, Psorex, Psorin, Therapsor; Mexico: Clobesol, Clobexpro, Clobxifoam, Dermatovate, Lobevat.
Asia
Japan: Delspart, Dermovate, Dertopica, Entyfluson, Glydil, Mahady, Myalone, Solvega.
Drug combinations
Clobetasol and Ammonium
Clobetasol, Neomycin, and Nystatin
Chemistry
Clobetasol Propionate: C~25~H~32~ClFO~5~. Mw: 466.97. (1) Pregna-1,4-diene-3,20-dione, 21-chloro-9-fluoro-11-hydroxy-16-methyl-17-(1-oxopropoxy)-, (11β,16β)-; (2) 21-Chloro-9-fluoro-11β,17-dihydroxy-16β-methylpregna-1,4-diene-3,20-dione 17-propionate. CAS-25122-46-7; CAS-25122-41-2 (clobetasol)(1983).
Pharmacologic Category
Skin and Mucous Membrane Agents; Anti-inflammatory Agents. Topical Corticosteroid. (ATC-Code: D07AD01).
Mechanism of action
Precise mechanism of action for topical anti-inflammatory activity is unknown. Therapeutic benefit in the management of corticosteroid-responsive dermatoses mediated primarily through anti-inflammatory, antipruritic, and vasoconstrictive actions. Anti-inflammatory effects may occur through induction of phospholipase A~2~ inhibitory proteins (lipocortins). Decreased arachidonic acid release from membrane phospholipids. Decreased arachidonic acid precursors may downregulate biosynthesis of potent inflammatory mediators (e.g. prostaglandins, leukotrienes).
Therapeutic use
Short-term relief of inflammation and pruritus associated with corticosteroid-responsive dermatoses.
Pregnancy and lactiation implications
Extensive use in pregnant women is not recommended. Teratogenic effects in animal studies. There are no adequate studies in pregnant women. Excretion in breast milk unknown (use caution).
Unlabeled use
Contraindications
Hypersensitivity to clobetasol or any component of the formulation. Viral, fungal, or tubercular skin lesions.
Warnings and precautions
Systemic absorption of topical corticosteroids may cause hypothalamic-pituitary-adrenal axis suppression (reversible) particularly in younger children, and leads to adrenal crisis. Allergic contact dermatitis can occur. Prolonged treatment with corticosteroids has been associated with the development of Kaposi’s sarcoma. Adverse systemic effects including hyperglycemia, glycosuria, fluid and electrolyte changes, and hypothalamic-pituitary-adrenal axis suppression may occur. Use in children <12 years of age is not recommended. Do not use on the face, axillae, or groin.